Cargando…

NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial

BACKGROUND: Surgery remains the standard of care for localised renal cell carcinoma (RCC). Nevertheless, nearly 50% of patients with high-risk disease experience relapse after surgery, with distant sites being common. Considering improved outcomes in terms of disease-free survival with adjuvant immu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Muhammad, Wood, Simon, Pryor, David, Moon, Daniel, Bressel, Mathias, Azad, Arun A., Mitchell, Catherine, Murphy, Declan, Zargar, Homi, Hardcastle, Nick, Kearsley, Jamie, Eapen, Renu, Wong, Lih Ming, Cuff, Katharine, Lawrentschuk, Nathan, Neeson, Paul J., Siva, Shankar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10164766/ https://www.ncbi.nlm.nih.gov/pubmed/37168818 http://dx.doi.org/10.1016/j.conctc.2023.101145

Ejemplares similares

A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol
por: Pryor, David, et al.
Publicado: (2021)

TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II
por: Siva, Shankar, et al.
Publicado: (2018)

RPN (Radius, Position of tumour, iNvasion of renal sinus) Classification and Nephrometry Scoring System: An Internationally Developed Clinical Classification To Describe the Surgical Difficulty for Renal Masses for Which Robotic Partial Nephrectomy Is Planned
por: Agarwal, Dinesh K., et al.
Publicado: (2023)

Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma
por: Udovicich, Cristian, et al.
Publicado: (2022)

P1066: PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.
por: Dickinson, Michael, et al.
Publicado: (2023)

Review of the use of prophylactic drain tubes post‐robotic radical prostatectomy: Dogma or decent practice?
por: Nzenza, Tatenda C., et al.
Publicado: (2020)

Open partial nephrectomy: current review
por: O’Connor, Ellen, et al.
Publicado: (2020)

Personalising treatment plan quality review with knowledge-based planning in the TROG 15.03 trial for stereotactic ablative body radiotherapy in primary kidney cancer
por: Hardcastle, Nicholas, et al.
Publicado: (2021)

Safety, Efficacy, and Patterns of Failure After Single-Fraction Stereotactic Body Radiation Therapy (SBRT) for Oligometastases
por: Sogono, Paolo, et al.
Publicado: (2021)

Effects of Partial Nephrectomy on Postoperative Blood Pressure
por: Lawrentschuk, Nathan, et al.
Publicado: (2012)

Stereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR)
por: Alomran, Reem, et al.
Publicado: (2021)

BSBM-15 SYSTEMIC AND LOCAL IMMUNE RESPONSES FOLLOWING STEREOTACTIC RADIOSURGERY TO BRAIN METASTASES FROM HER2-AMPLIFIED BREAST CANCER
por: Sia, Joseph, et al.
Publicado: (2023)

An analysis of respiratory induced kidney motion on four-dimensional computed tomography and its implications for stereotactic kidney radiotherapy
por: Siva, Shankar, et al.
Publicado: (2013)

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
por: David, Steven, et al.
Publicado: (2019)

A randomised phase II trial of Stereotactic Ablative Fractionated radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the lung (TROG 13.01 SAFRON II)
por: Siva, Shankar, et al.
Publicado: (2016)

EDITORIAL COMMENT: OFF-CLAMP ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY
por: Bozin, Mike, et al.
Publicado: (2016)

A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer
por: Akanda, Zarique Z., et al.
Publicado: (2021)

National nephrectomy registries: Reviewing the need for population-based data
por: Pearson, John, et al.
Publicado: (2015)

Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy
por: Leone, Andrew, et al.
Publicado: (2016)

Treatment Time Optimization in Single Fraction Stereotactic Ablative Radiation Therapy: A 10-Year Institutional Experience
por: Gaudreault, Mathieu, et al.
Publicado: (2022)

Pembrolizumab-induced encephalitis in a patient with renal cell carcinoma post nephrectomy: A case report
por: Sharma, Amit, et al.
Publicado: (2023)

Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer
por: Corrò, Claudia, et al.
Publicado: (2022)

NEO E-vita—NEO era!
por: Jakob, Heinz, et al.
Publicado: (2022)

NaF PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy
por: Hardcastle, Nicholas, et al.
Publicado: (2019)

Improving the productivity and efficiency of vascular surgery and radiology multidisciplinary meetings
por: Dobson, Gary, et al.
Publicado: (2015)

Malignant ascites following radical nephrectomy for cystic renal cell carcinoma
por: Soputro, Nicolas Adrianto, et al.
Publicado: (2021)

Robotic pyelolithotomy for staghorn nephrolithiasis during partial nephrectomy
por: Andrade, Hiury S., et al.
Publicado: (2016)

Salvage Robot-Assisted Partial Nephrectomy for the Management of Renal Cell Carcinoma Following Failed Stereotactic Radiotherapy
por: Gorin, Michael A., et al.
Publicado: (2012)

Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer—a narrative review
por: Ong, Sean, et al.
Publicado: (2021)

Neo-Salvarsan
Publicado: (1912)

Out-of-field dose in stereotactic radiotherapy for paediatric patients
por: Garrett, Lachlan, et al.
Publicado: (2021)

A case of metastatic renal cell carcinoma successfully treated with deferred cytoreductive nephrectomy following lenvatinib plus pembrolizumab combination therapy
por: Sato, Hiroaki, et al.
Publicado: (2023)

Safety first: evidence for delay of radical prostatectomy without use of androgen deprivation therapy during COVID-19
por: Sean Ong, Xuan Rui, et al.
Publicado: (2020)

Oracle database cloud cookbook with Oracle Enterprise Manager Cloud Control 13c
por: Havewala, Porus Homi
Publicado: (2017)

Oracle Enterprise Manager Cloud Control 12c: managing data center chaos
por: Havewala, Porus Homi
Publicado: (2012)

cyNeo4j: connecting Neo4j and Cytoscape
por: Summer, Georg, et al.
Publicado: (2015)

Neo-Darwinists and Neo-Aristotelians: how to talk about natural purpose
por: Woodford, Peter
Publicado: (2016)

The land of the past? Neo-populism, neo-fascism, and the failure of the left in Brazil
por: de Souza, Marcelo Lopes
Publicado: (2020)

Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment
por: Anderson, Erik S., et al.
Publicado: (2017)

Combination of Pembrolizumab and Stereotactic Body Radiation Therapy in Recurrent Metastatic Penile Squamous Cell Carcinoma: A Case Study
por: Kaakour, Dalia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nbi9ov79d9vvr9ss8mjs2o67e4